Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ABL and SANOFI to collaborate on the development of ABL301, a potential first-in-class bispecific antibody targeting alpha-synuclein and containing a proprietary brain shuttle, for alpha-synucleinopathies, including Parkinson's disease ABL301 uses ABL's Grabody-B platform technology to effectively cross the blood-brain barrier ABL to receive $75M upfront and up to $985M in potential milestone payments for exclusive global license to ABL301 SEONGNAM, South Korea, Jan. 11, 2022 /PRNewswire/ -- ABL Bio, Inc. (KOSDAQ: 298380), a clinical-stage biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, today announced an exclusive collaboration and worldwide license agreement with SANOFI to develop and commercialize ABL301, a pre-clinical stage bispecific antibody targeting alpha-synuclein and IGF1R to treat Parkinson's disease and other potential indications with enhanced blood-brain barrier (BBB) penetration. Under the terms of the agreement, ABL will receive $75 million in upfront payments.

ABL Bio Enters Global Collaboration and License Agreement with SANOFI to Advance ABL301 for the Treatment of Parkinson's Disease

Sanofi (SNY) CEO Paul Hudson Presents at JPMorgan 40th Annual Healthcare Conference (Transcript)

ExScientia Ltd

Shares of Exscientia PLC ( EXAI , Financial) got a nice boost last week when the U.K.-based biotech announced it signed a research collaboration and license agreement with large drugmaker Sanofi SA ( SNY , Financial) that could be worth $5.2 billion.

Shares of Sanofi, Exscientia Rise on News of Collaboration

Sanofi (SNY) signs a collaboration agreement with Exscientia to develop precision-engineered medicines in oncology and immunology using the latter's AI-driven platform.

Sanofi (SNY) Inks Deal to Develop AI-Driven Precision Medicines

Amcor Plc

British American Tobacco

Imperial Brands PLC

Leggett & Platt

Novartis

Realty Income Corp

Red Electrica Corp SA

Swiss Re AG

AT&T

Unilever

V.F.

Exxon Mobil

Kiplinger "insights for investors" online, first published 91 "Top Dividend Stocks From Around The World" 7/13/20. Two Kiplinger articles provided this 105 Best Dividend Stocks on Earth list compiled 7/1/21.

Buy Signals Sound For 14 Top January Dividends On Earth

Akoya Biosciences Inc

Alnylam Pharmaceuticals

Biohaven Pharmaceutical Hld

These biotech stocks could be worth watching in 2022.

Which Stocks To Buy Now? 4 Biotech Stocks To Know

Shares of Exscientia EXAI, -2.05% jumped 14.3% in premarket trading on Friday after it announced a deal with Sanofi SNY, -0.24% to develop up to 15 new oncology and immunology drug candidates using Exscientia's artificial intelligence platform. Sanofi's stock was up 0.8%.

Sanofi, Exscientia sign development deal worth up to $5.2 billion

Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines

Intel

Merck

Roche Holding AG

T. Rowe Price Group

Western Union

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating).

Wide-Moat Stocks On Sale - The January 2022 Heat Map

A French court ruled on Wednesday that families of victims of Depakine, an epilepsy drug that caused birth defects and learning difficulties when taken during pregnancy, could join a class action lawsuit against drugmaker Sanofi, France Info radio reported, quoting news agency AFP.

French court backs class action against Sanofi over Depakine drug - media

Sanofi SA (NASDAQ: SNY) says the preliminary estimate of currency impact on Q4 sales and business EPS is approximately +1.5% and +2.5%. Also, the Company expects vaccines sales for Q4 FY21 to be below Q4 FY20.

Sanofi Expects Q4 FY21 Vaccine Sales Lower Than Year-Ago, Positive Currency Impact

Sanofi (SNY) inks a deal to acquire privately-held Amunix Pharmaceuticals, which will add potentially transformative cancer therapies to its immuno-oncology pipeline.

Sanofi (SNY) to Acquire Amunix, Boost Immuno-oncology Pipeline

Shares of Sanofi SNY, +0.18% gained 0.8% in trading on Tuesday after the company announced plans to buy Amunix Pharmaceuticals Inc., a privately held immuno-oncology company. The acquisition is worth $1 billion upfront and another $225 million in milestone payments.

Sanofi to buy immuno-oncology company Amunix for $1 billion

Sanofi SA (NASDAQ: SNY) will buy an immuno-oncology company, Amunix Pharmaceuticals Inc, for an upfront payment of about $1 billion. Sanofi will also pay Amunix up to $225 million based on certain future development milestones.

Sanofi Agrees To Buy US-Based Amunix Pharma For $1B Upfront

Drugmaker Sanofi SA will buy Amunix Pharmaceuticals Inc for an upfront payment of about $1 billion, marking the latest acquisition by the French drugmaker in the U.S. biotech sphere as Sanofi aims to offset COVID-19 vaccine setbacks.

Sanofi in $1 billion deal to buy U.S.-based Amunix Pharma

Sanofi to acquire Amunix immun o -oncology pipeline with next generation C onditionally A ctivated B iologics

Sanofi to acquire Amunix immuno-oncology pipeline with next generation Conditionally Activated Biologics

Gilles SCHNEPP takes over as Chairman of the Appointments, Governance and CSR Committee of Sanofi PARIS – December 16, 2021 - On December 15, 2021, the Board of Directors appointed Gilles Schnepp, an independent director of Sanofi, as Chairman of the Appointments, Governance and CSR Committee. Gilles Schnepp leaves his position on the Audit Committee.

Press Release: Gilles SCHNEPP takes over as Chairman of the Appointments, Governance and CSR Committee of Sanofi

GlaxoSmithKline

Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline Plc (NYSE: GSK) expect data from late-stage trials of its COVID-19 booster dose in Q1 2022, instead of this year. The news came as the companies shared preliminary data from trials that showed the single-dose booster provided strong immune responses.

Sanofi, Glaxo's COVID-19 Vaccine Candidate Works As Booster, But Data Readout Pushed Back

The vaccine's release will be pushed back to 2022 following delays to main clinical trials, the companies said.

Sanofi, GSK Say Covid Vaccine Works As Booster Shot

GlaxoSmithKline PLC (LSE:GSK) said the Covid-19 vaccine it is developing with French group Sanofi proved effective as a booster shot in a major independent trial. The vaccine boosted Covid-neutralising antibodies by a factor of 9 to 43 whatever primary vaccines ((AstraZeneca, Johnson & Johnson (NYSE:JNJ), Moderna, Pfizer/BioNTech) had been received and for all age groups with good safety and tolerability.

GlaxoSmithKline/Sanofi Covid-19 vaccine effective as booster shot, trial shows

Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation

Sanofi SA (NASDAQ: SNY) presented data from two Phase 3 studies of fitusiran for the prophylactic treatment with hemophilia A or B, with or without inhibitors. Data were shared at the American Society of Hematology (ASH) Annual Meeting.

Sanofi Reveals Late-Stage Data For Fitusiran In Hemophilia Patients

Sanofi's (SNY) phase III study on Sarclisa is the first to meet the primary endpoint of MRD negativity in transplant-eligible patients with newly diagnosed multiple myeloma.

Sanofi (SNY) Multiple Myeloma Phase III Study Meets Goal

Johnson & Johnson

Sanofi SA (NASDAQ: SNY) and Johnson & Johnson (NYSE: JNJ) posted new data from their myeloma therapies, Sarclisa and Darzalex, respectively. Data were shared at the American Society of Hematology (ASH) 2021 Annual Meeting.

Comparing Data: Sanofi Vs. Johnson & Johnson Multiple Myeloma Therapies In Newly Diagnosed Patients

Cardinal Health

Kiplinger "insights for investors" online, first-published 91 "Top Dividend Stocks From Around The World" 7/13/20. Two Kiplinger articles provided this 105 Best Dividend Stocks on Earth compiled 7/1/21. 40 European “Dividend Aristocrats,” showed 10 years of stable or increasing dividends; 65 S&P 500 Aristocrats showed 25 years of increases for U.S. companies.

News for Sanofi Stock (SNY)